Australian IVF screening start-up pulls Nasdaq IPO, blames US tariffs

Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe. Already a subscriber? Login An Australian technology start-up, which has developed a test to screen embryos for thousands of genetic diseases, has ditched its plan to list on the Nasdaq, after the chairman blamed US President Donald Trump’s tariff chaos for spooking investors. GenEmbryomics had been preparing for its float for 18 months, but failed to raise the full $US5.

3 million ($8.4 million) for its initial public offering by April 8, a date that coincided with the bottom of the sharp global sharemarket correction triggered by Trump’s tariff policies. Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe.



Already a subscriber? Login Introducing your Newsfeed Follow the topics, people and companies that matter to you. Latest In Technology Fetching latest articles Most Viewed In Technology BOSS Financial Review.